Phase I Study of CPD704 Inhalation Suspension in Healthy Subjects
This study tests a new inhaled medication called CPD704 in healthy adults to understand how it works in the body and ensure it is safe to use. Participants will receive either single or multiple doses of the medication while researchers monitor for any side effects and measure how the body processes the drug.
Key Objective:This trial is testing whether CPD704 inhalation suspension is safe and well-tolerated, which could lead to a new treatment option for patients who need inhaled medication in the future.
Who to Consider:Healthy Chinese adults interested in contributing to early-stage drug development and willing to undergo close medical monitoring should consider enrolling in this study.
Trial Parameters
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
Brief Summary
This is a Phase I clinical trial evaluating the safety, tolerability, and pharmacokinetic characteristics of single and multiple doses of CPD704 inhalation suspension in healthy Chinese adult subjects.
Eligibility Criteria
Inclusion Criteria: 1. The subject can communicate well with the researchers, fully understand the purpose and requirements of this trial, voluntarily participate in the clinical trial and sign the written informed consent form; 2. Healthy subjects aged 18-55 years (including the boundary value, subject to the time of signing the informed consent form), male or female; 3. Body mass index (BMI) within the range of 19 \~ 28 kg/m2 (including the critical value), male weight ≥ 50 kg, female weight ≥ 45 kg; 4. The subject has no plans to give birth, sperm or egg donation from the signing of the informed consent form to 90 days after medication, and voluntarily takes medically approved contraceptive measures (including his partner) Exclusion Criteria: 1. Patients who have taken any clinical trial drugs or participated in any drug clinical trial within 3 months before signing the ICF, or participated in other medical research activities, and are not suitable for participating in this trial as